/PRNewswire/ Nasus Pharma a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address.
/PRNewswire/ Nasus Pharma a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address.
NP-003 study terminated early with high significance in reducing viral infection. TEL AVIV , Israel, Nov. 24, 2021 /PRNewswire/ Nasus Pharma a privately held clinical-stage biopharmaceutical
Safety of Taffix reaffirmed
LONDON, March 17, 2021 /PRNewswire/ A leading biopharma company and makers of rapid delivery innovation for life-saving medicines - Nasus Pharma - stands behind its nasal spray, Taffix, reassuring the public of its safety and clinical efficacy. Taffix is built on an existing, proven, medical technology, which is already used in many nasal sprays to combat allergies and the common cold viruses.
Contrary to the wording in an email regarding Taffix Nasal Spray sent to customers in some countries by a retail company selling the product, Taffix is totally safe and legitimately available for sale in Europe by reference to its valid European Conformity market.